Sorry, you need to enable JavaScript to visit this website.

XALKORI® (crizotinib) Clinical Studies

14 CLINICAL STUDIES

14.1 ALK-Positive Metastatic NSCLC

Previously Untreated ALK-Positive Metastatic NSCLC - Study 1 (PROFILE 1014; NCT01154140)

The efficacy of XALKORI for the treatment of patients with ALK-positive metastatic NSCLC, who had not received previous systemic treatment for advanced disease, was demonstrated in a randomized, multicenter, open-label, active-controlled study (Study 1). Patients were required to have ALK-positive NSCLC as identified by the FDA-approved assay, Vysis ALK Break-Apart fluorescence in situ hybridization (FISH) Probe Kit, prior to randomization. The major efficacy outcome measure was progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by independent radiology review (IRR) committee. Additional efficacy outcome measures included objective response rate (ORR) as assessed by IRR, duration of response (DOR), and overall survival (OS). Patient-reported lung cancer symptoms were assessed at baseline and periodically during treatment.

Patients were randomized to receive XALKORI (n=172) or chemotherapy (n=171). Randomization was stratified by Eastern Cooperative Oncology Group (ECOG) performance status (0–1, 2), race (Asian, non-Asian), and brain metastases (present, absent). Patients in the XALKORI arm received XALKORI 250 mg orally twice daily until documented disease progression, intolerance to therapy, or the investigator determined that the patient was no longer experiencing clinical benefit. Chemotherapy consisted of pemetrexed 500 mg/m2 with cisplatin 75 mg/m2 or carboplatin AUC of 5 or 6 mg×min/mL by intravenous infusion every 3 weeks for up to 6 cycles. Patients in the chemotherapy arm were not permitted to receive maintenance chemotherapy. At the time of documented disease progression, as per independent radiology review, patients randomized to chemotherapy were offered XALKORI.

The demographic characteristics of the overall study population were 62% female, median age of 53 years, baseline ECOG performance status 0 or 1 (95%), 51% White and 46% Asian, 4% current smokers, 32% past smokers, and 64% never smokers. The disease characteristics of the overall study population were metastatic disease in 98% of patients, 92% of patients' tumors were classified as adenocarcinoma histology, 27% of patients had brain metastases, and 7% received systemic chemotherapy as adjuvant or neoadjuvant therapy. At the time of the final analysis of overall survival, 84% of patients randomized to the chemotherapy arm subsequently received XALKORI.

Study 1 demonstrated a statistically significant improvement in PFS in patients treated with XALKORI. There was no statistically significant difference in OS between patients treated with XALKORI and patients treated with chemotherapy. Table 7 and Figure 1 summarize the efficacy results. Exploratory patient-reported symptom measures of baseline and post-treatment dyspnea, cough, and chest pain suggested a delay in time to development of or worsening of dyspnea, but not cough or chest pain, in patients treated with XALKORI as compared to chemotherapy. The patient-reported delay in onset or worsening of dyspnea may be an overestimation, because patients were not blinded to treatment assignment.

Table 7. Previously Untreated ALK-Positive Metastatic NSCLC - Efficacy Results in Study 1
XALKORI
(N=172)
Chemotherapy
(N=171)
HR=hazard ratio; CI=confidence interval; IRR=independent radiology review; NR=not reached; CR=complete response; PR=partial response.
*
Based on the Cox proportional hazards stratified analysis.
Based on the stratified log-rank test.
Based on the stratified Cochran-Mantel-Haenszel test.
Progression-Free Survival (Based on IRR)
  Number of Events (%) 100 (58%) 137 (80%)
    Progressive Disease 89 (52%) 132 (77%)
    Death 11 (6%) 5 (3%)
  Median, Months (95% CI) 10.9 (8.3, 13.9) 7.0 (6.8, 8.2)
  HR (95% CI)* 0.45 (0.35, 0.60)
  p-value <0.001
Overall Survival
  Number of Events (%) 71 (41%) 81 (47%)
  Median, Months (95% CI) NR (45.8, NR) 47.5 (32.2, NR)
  HR (95% CI)* 0.76 (0.55, 1.05)
  p-value 0.098
Tumor Responses (Based on IRR)
  Objective Response Rate % (95% CI) 74% (67, 81) 45% (37, 53)
    CR, n (%) 3 (1.7%) 2 (1.2%)
    PR, n (%) 125 (73%) 75 (44%)
  p-value <0.001
Duration of Response
  Median, Months (95% CI) 11.3 (8.1, 13.8) 5.3 (4.1, 5.8)
Figure 1. Kaplan-Meier Curves of Progression-Free Survival as Assessed by IRR in Study 1
Figure 1

Previously Treated ALK-Positive Metastatic NSCLC - Study 2 (PROFILE 1007; NCT00932893)

The efficacy of XALKORI as monotherapy for the treatment of 347 patients with ALK-positive metastatic NSCLC, previously treated with 1 platinum-based chemotherapy regimen, were demonstrated in a randomized, multicenter, open-label, active-controlled study (Study 2). The major efficacy outcome was PFS according to RECIST version 1.1 as assessed by IRR. Additional efficacy outcomes included ORR as assessed by IRR, DOR, and OS.

Patients were randomized to receive XALKORI 250 mg orally twice daily (n=173) or chemotherapy (n=174). Chemotherapy consisted of pemetrexed 500 mg/m2 (if pemetrexed-naïve; n=99) or docetaxel 75 mg/m2 (n=72) intravenously (IV) every 21 days. Patients in both treatment arms continued treatment until documented disease progression, intolerance to therapy, or the investigator determined that the patient was no longer experiencing clinical benefit. Randomization was stratified by ECOG performance status (0–1, 2), brain metastases (present, absent), and prior EGFR tyrosine kinase inhibitor treatment (yes, no). Patients were required to have ALK-positive NSCLC as identified by the FDA-approved assay, Vysis ALK Break-Apart FISH Probe Kit, prior to randomization.

The demographic characteristics of the overall study population were 56% female, median age of 50 years, baseline ECOG performance status 0 or 1 (90%), 52% White and 45% Asian, 4% current smokers, 33% past smokers, and 63% never smokers. The disease characteristics of the overall study population were metastatic disease in at least 95% of patients and at least 93% of patients' tumors were classified as adenocarcinoma histology. At the time of the final analysis of overall survival, 89% of patients randomized to the chemotherapy arm subsequently received XALKORI.

Study 2 demonstrated a statistically significant improvement in PFS in the patients treated with XALKORI. Table 8 and Figure 2 summarize the efficacy results.

Table 8. Previously Treated ALK-Positive Metastatic NSCLC - Efficacy Results in Study 2
XALKORI
(N=173)
Chemotherapy
(N=174)
HR=hazard ratio; CI=confidence interval; IRR=independent radiology review; CR=complete response; PR=partial response.
*
For pemetrexed, the median PFS was 4.2 months. For docetaxel, the median PFS was 2.6 months.
Based on the Cox proportional hazards stratified analysis.
Based on the stratified log-rank test.
§
Based on the stratified Cochran-Mantel-Haenszel test.
Progression-Free Survival (Based on IRR)
  Number of Events (%) 100 (58%) 127 (73%)
    Progressive Disease 84 (49%) 119 (68%)
    Death 16 (9%) 8 (5%)
  Median, Months (95% CI) 7.7 (6.0, 8.8) 3.0* (2.6, 4.3)
  HR (95% CI) 0.49 (0.37, 0.64)
  p-value <0.001
Overall Survival
  Number of Events (%) 116 (67%) 126 (72%)
  Median, Months (95% CI) 21.7 (18.9,30.5) 21.9 (16.8,26.0)
  HR (95% CI) 0.85 (0.66, 1.10)
  p-value 0.229
Tumor Responses (Based on IRR)
  Objective Response Rate % (95% CI) 65% (58, 72) 20% (14, 26)
    CR, n (%) 1 (0.6%) 0
    PR, n (%) 112 (65%) 34 (20%)
  p-value§ <0.001
Duration of Response
  Median, Months (95% CI) 7.4 (6.1, 9.7) 5.6 (3.4, 8.3)
Figure 2. Kaplan-Meier Curves of Progression-Free Survival as Assessed by IRR in Study 2
Figure 2

14.2 ROS1-Positive Metastatic NSCLC

ROS1-Positive Metastatic NSCLC - Study 3 (PROFILE 1001; NCT00585195)

The efficacy and safety of XALKORI was investigated in a multicenter, single-arm study (Study 3), in which patients with ROS1-positive metastatic NSCLC received XALKORI 250 mg orally twice daily. Patients were required to have histologically-confirmed advanced NSCLC with a ROS1 rearrangement, age 18 years or older, ECOG performance status of 0, 1, or 2, and measurable disease. The efficacy outcome measures were ORR and DOR according to RECIST version 1.0 as assessed by IRR and investigator, with imaging performed every 8 weeks for the first 60 weeks.

Baseline demographic and disease characteristics were female (56%), median age of 53 years, baseline ECOG performance status of 0 or 1 (98%), White (54%), Asian (42%), past smokers (22%), never smokers (78%), metastatic disease (92%), adenocarcinoma (96%), no prior systemic therapy for metastatic disease (14%), and prior platinum-based chemotherapy for metastatic disease (80%). The ROS1 status of NSCLC tissue samples was determined by laboratory-developed break-apart FISH (96%) or RT-PCR (4%) clinical trial assays. For assessment by FISH, ROS1 positivity required that ≥15% of a minimum of 50 evaluated nuclei contained a ROS1 gene rearrangement.

Efficacy results are summarized in Table 9.

Table 9. ROS1-Positive Metastatic NSCLC - Results* in Study 3
Efficacy Parameters IRR
(N=50)
Investigator-Assessed
(N=50)
IRR=independent radiology review; CI=confidence interval; NR=not reached.
*
As assessed by RECIST version 1.0.
Objective Response Rate (95% CI) 66% (51, 79) 72% (58, 84)
  Complete Response, n 1 5
  Partial Response, n 32 31
Duration of Response
  Median, Months (95% CI) 18.3 (12.7, NR) NR (14.5, NR)

What's New

No Current Announcements.

Therapeutic Area

Contact Pfizer Medical

Report an Adverse Event
1-800-438-1985

Search

Please enter your search term(s) for XALKORI®

Contact Pfizer

Need to report an Adverse Event, Side Effect or Product Quality Concern?

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or www.fda.gov/MedWatch

Have a Medical Question on a Pfizer Prescription Medicine?
Contact Pfizer Medical Information to speak with a professional regarding your medical question on a Pfizer prescription product: (800) 438-1985
Have a Question on a Pfizer Over-the-Counter Product?
For Pfizer Consumer Healthcare non-prescription or over-the-counter products such as Advil, Centrum, Nexium or Thermacare, call (800) 322-3129
Have a Question about Pfizer Clinical Trials?
If you are looking for information about Pfizer studies currently recruiting new patients in your area, you can begin your search on our website. For questions about a Pfizer Clinical Trial, call (800) 718-1021 or email [email protected]
Need Information on Pfizer’s Patient Assistance Programs?

Pfizer RxPathways® connects eligible patients, regardless of their insurance status, to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. For more information, please call (844) 989-7284 or visit www.PfizerRxPathways.com.

Eligible patients can register for valuable savings offers for nearly 40 brand name medications. Visit www.MyPfizerBrands.com for more information.